Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide.

Wendler J, Schroeder BO, Ehmann D, Koeninger L, Mailänder-Sánchez D, Lemberg C, Wanner S, Schaller M, Stange EF, Malek NP, Weidenmaier C, LeibundGut-Landmann S, Wehkamp J.

Sci Rep. 2019 Mar 6;9(1):3640. doi: 10.1038/s41598-019-40216-2.

2.

Are the changes in diagnostic criteria for gestational diabetes mellitus reflected in perinatal outcomes? A retrospective assessment.

Ehmann DMT, Hickman PE, Potter JM.

Aust N Z J Obstet Gynaecol. 2019 Feb 27. doi: 10.1111/ajo.12956. [Epub ahead of print]

PMID:
30811589
3.

Paneth cell α-defensins HD-5 and HD-6 display differential degradation into active antimicrobial fragments.

Ehmann D, Wendler J, Koeninger L, Larsen IS, Klag T, Berger J, Marette A, Schaller M, Stange EF, Malek NP, Jensen BAH, Wehkamp J.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3746-3751. doi: 10.1073/pnas.1817376116. Epub 2019 Feb 11.

4.

Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.

Iskenderian A, Liu N, Deng Q, Huang Y, Shen C, Palmieri K, Crooker R, Lundberg D, Kastrapeli N, Pescatore B, Romashko A, Dumas J, Comeau R, Norton A, Pan J, Rong H, Derakhchan K, Ehmann DE.

Skelet Muscle. 2018 Oct 27;8(1):34. doi: 10.1186/s13395-018-0180-z.

5.

β-Defensin 1 Is Prominent in the Liver and Induced During Cholestasis by Bilirubin and Bile Acids via Farnesoid X Receptor and Constitutive Androstane Receptor.

Klag T, Thomas M, Ehmann D, Courth L, Mailänder-Sanchez D, Weiss TS, Dayoub R, Abshagen K, Vollmar B, Thasler WE, Stange EF, Berg CP, Malek NP, Zanger UM, Wehkamp J.

Front Immunol. 2018 Jul 27;9:1735. doi: 10.3389/fimmu.2018.01735. eCollection 2018.

6.

TOPICAL DORZOLAMIDE-TIMOLOL WITH INTRAVITREOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR RETINAL VEIN OCCLUSION: A PILOT STUDY.

Obeid A, Hsu J, Ehmann D, Gao X, Sridhar J, Chiang A, Park CH, Ho AC.

Retin Cases Brief Rep. 2018 Jun 1. doi: 10.1097/ICB.0000000000000752. [Epub ahead of print]

PMID:
29864044
7.

Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application.

Shen C, Iskenderian A, Lundberg D, He T, Palmieri K, Crooker R, Deng Q, Traylor M, Gu S, Rong H, Ehmann D, Pescatore B, Strack-Logue B, Romashko A, Baviello G, Gill J, Zhang B, Meiyappan M, Pan C, Norton AW.

J Pharmacol Exp Ther. 2018 Aug;366(2):291-302. doi: 10.1124/jpet.118.248195. Epub 2018 May 11.

PMID:
29752426
8.

Patient Comfort with Yellow (577 nm) vs. Green (532 nm) Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.

Adam MK, Weinstock BM, Kasi SK, Ehmann DS, Hsu J, Garg SJ, Ho AC, Chiang A.

Ophthalmol Retina. 2018 Feb;2(2):91-95. doi: 10.1016/j.oret.2017.05.012. Epub 2017 Aug 9.

PMID:
31047351
9.

Bacterial Periplasmic Oxidoreductases Control the Activity of Oxidized Human Antimicrobial β-Defensin 1.

Wendler J, Ehmann D, Courth L, Schroeder BO, Malek NP, Wehkamp J.

Infect Immun. 2018 Mar 22;86(4). pii: e00875-17. doi: 10.1128/IAI.00875-17. Print 2018 Apr.

10.

ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O'Donnell J, Mueller JP, Tommasi RA, Miller AA.

Nat Microbiol. 2017 Jun 30;2:17104. doi: 10.1038/nmicrobiol.2017.104.

PMID:
28665414
11.

A CASE OF INTRAVESICAL BACILLUS CALMETTE-GUERIN-RELATED ENDOPHTHALMITIS AND RETINITIS CONFIRMED WITH RETINAL BIOPSY.

Huggins A, Adam M, Ehmann D, Eagle RC, Malloy B, Garg SJ.

Retin Cases Brief Rep. 2017 Jun 20. doi: 10.1097/ICB.0000000000000608. [Epub ahead of print]

PMID:
28644177
12.

Bilateral Retinal Problem in a Patient With Alport Syndrome.

Kasi SK, Adam MK, Ehmann DS.

JAMA Ophthalmol. 2017 Sep 1;135(9):995-996. doi: 10.1001/jamaophthalmol.2017.0036. No abstract available.

PMID:
28594982
13.

BILATERAL OCCIPITAL POLE HYPERTENSIVE STROKE DIAGNOSED WITH MACULAR INTEGRITY ASSESSMENT (MAIA) MICROPERIMETRY.

Kasi SK, Shahlaee A, Adam MK, Ehmann DS, Sivalingam A.

Retin Cases Brief Rep. 2017 Winter;11 Suppl 1:S170-S173. doi: 10.1097/ICB.0000000000000403.

PMID:
28009776
14.

Cataract surgery and age-related macular degeneration.

Ehmann DS, Ho AC.

Curr Opin Ophthalmol. 2017 Jan;28(1):58-62. Review.

PMID:
27684293
15.

HEMORRHAGIC OCCLUSIVE RETINAL VASCULITIS AND NONHEMORRHAGIC VASCULITIS AFTER UNCOMPLICATED CATARACT SURGERY WITH INTRACAMERAL VANCOMYCIN.

Ehmann DS, Adam MK, Kasi SK, Sivalingam A, Dunn JP.

Retin Cases Brief Rep. 2017 Winter;11 Suppl 1:S155-S158. doi: 10.1097/ICB.0000000000000389.

PMID:
27552119
16.

Early Optical Coherence Tomography Findings after Vitreomacular Traction Release.

Rahimy E, Shahlaee A, Ehmann D, Rayess N, Fineman MS, Garg SJ, Ho AC, Hsu J.

Ophthalmology. 2016 Sep;123(9):2046-7. doi: 10.1016/j.ophtha.2016.04.045. Epub 2016 Jun 21. No abstract available.

PMID:
27338012
17.

En Face Optical Coherence Tomography and Optical Coherence Tomography Angiography Imaging of Taxane-Associated Cystoid Macular Edema.

Sridhar J, Shahlaee A, Ehmann D, Samara WA, Rahimy E, Ho AC, Chiang A.

Ophthalmic Surg Lasers Imaging Retina. 2016 Feb;47(2):176-9. doi: 10.3928/23258160-20160126-12.

PMID:
26878452
18.

Cell therapy for retinal disease.

Ehmann D, Shahlaee A, Ho AC.

Curr Opin Ophthalmol. 2016 May;27(3):185-90. doi: 10.1097/ICU.0000000000000254. Review.

PMID:
26859132
19.

Untargeted Metabolomics To Ascertain Antibiotic Modes of Action.

Vincent IM, Ehmann DE, Mills SD, Perros M, Barrett MP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2281-91. doi: 10.1128/AAC.02109-15. Print 2016 Apr.

20.

Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy.

Kim A, Kutschke A, Ehmann DE, Patey SA, Crandon JL, Gorseth E, Miller AA, McLaughlin RE, Blinn CM, Chen A, Nayar AS, Dangel B, Tsai AS, Rooney MT, Murphy-Benenato KE, Eakin AE, Nicolau DP.

Antimicrob Agents Chemother. 2015 Dec;59(12):7743-52. doi: 10.1128/AAC.00831-15. Epub 2015 Oct 5.

21.

Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.

Kern G, Palmer T, Ehmann DE, Shapiro AB, Andrews B, Basarab GS, Doig P, Fan J, Gao N, Mills SD, Mueller J, Sriram S, Thresher J, Walkup GK.

J Biol Chem. 2015 Aug 21;290(34):20984-94. doi: 10.1074/jbc.M115.663534. Epub 2015 Jul 6.

22.

Translating slow-binding inhibition kinetics into cellular and in vivo effects.

Walkup GK, You Z, Ross PL, Allen EK, Daryaee F, Hale MR, O'Donnell J, Ehmann DE, Schuck VJ, Buurman ET, Choy AL, Hajec L, Murphy-Benenato K, Marone V, Patey SA, Grosser LA, Johnstone M, Walker SG, Tonge PJ, Fisher SL.

Nat Chem Biol. 2015 Jun;11(6):416-23. doi: 10.1038/nchembio.1796. Epub 2015 Apr 20.

23.

Discovery of efficacious Pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model.

Murphy-Benenato KE, Bhagunde PR, Chen A, Davis HE, Durand-Réville TF, Ehmann DE, Galullo V, Harris JJ, Hatoum-Mokdad H, Jahić H, Kim A, Manjunatha MR, Manyak EL, Mueller J, Patey S, Quiroga O, Rooney M, Sha L, Shapiro AB, Sylvester M, Tan B, Tsai AS, Uria-Nickelsen M, Wu Y, Zambrowski M, Zhao SX.

J Med Chem. 2015 Mar 12;58(5):2195-205. doi: 10.1021/jm501506f. Epub 2015 Mar 3.

PMID:
25658376
24.

Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii.

Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA.

Antimicrob Agents Chemother. 2015 Mar;59(3):1680-9. doi: 10.1128/AAC.04808-14. Epub 2015 Jan 5.

25.

The Impact of Bariatric Surgery on Diabetic Retinopathy: A Systematic Review and Meta-Analysis.

Cheung D, Switzer NJ, Ehmann D, Rudnisky C, Shi X, Karmali S.

Obes Surg. 2015 Sep;25(9):1604-9. doi: 10.1007/s11695-014-1539-9. Review.

PMID:
25515499
26.

Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48.

Lahiri SD, Mangani S, Jahić H, Benvenuti M, Durand-Reville TF, De Luca F, Ehmann DE, Rossolini GM, Alm RA, Docquier JD.

ACS Chem Biol. 2015 Feb 20;10(2):591-600. doi: 10.1021/cb500703p. Epub 2014 Dec 4.

PMID:
25406838
27.

Paneth cell α-defensin 6 (HD-6) is an antimicrobial peptide.

Schroeder BO, Ehmann D, Precht JC, Castillo PA, Küchler R, Berger J, Schaller M, Stange EF, Wehkamp J.

Mucosal Immunol. 2015 May;8(3):661-71. doi: 10.1038/mi.2014.100. Epub 2014 Nov 5.

28.

Target-based resistance in Pseudomonas aeruginosa and Escherichia coli to NBTI 5463, a novel bacterial type II topoisomerase inhibitor.

Nayar AS, Dougherty TJ, Reck F, Thresher J, Gao N, Shapiro AB, Ehmann DE.

Antimicrob Agents Chemother. 2015 Jan;59(1):331-7. doi: 10.1128/AAC.04077-14. Epub 2014 Oct 27.

29.

Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase.

Ehmann DE, Lahiri SD.

Curr Opin Pharmacol. 2014 Oct;18:76-83. doi: 10.1016/j.coph.2014.09.007. Epub 2014 Sep 29. Review.

30.

Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa.

Reck F, Ehmann DE, Dougherty TJ, Newman JV, Hopkins S, Stone G, Agrawal N, Ciaccio P, McNulty J, Barthlow H, O'Donnell J, Goteti K, Breen J, Comita-Prevoir J, Cornebise M, Cronin M, Eyermann CJ, Geng B, Carr GR, Pandarinathan L, Tang X, Cottone A, Zhao L, Bezdenejnih-Snyder N.

Bioorg Med Chem. 2014 Oct 1;22(19):5392-409. doi: 10.1016/j.bmc.2014.07.040. Epub 2014 Aug 4.

PMID:
25155913
31.

Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity.

Ehmann D, Greve M.

Can J Ophthalmol. 2014 Apr;49(2):228-31. doi: 10.1016/j.jcjo.2013.12.014. Epub 2014 Feb 28.

PMID:
24767234
32.

NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Dougherty TJ, Nayar A, Newman JV, Hopkins S, Stone GG, Johnstone M, Shapiro AB, Cronin M, Reck F, Ehmann DE.

Antimicrob Agents Chemother. 2014 May;58(5):2657-64. doi: 10.1128/AAC.02778-13. Epub 2014 Feb 24. Erratum in: Antimicrob Agents Chemother. 2014 Jul;58(7):4250.

33.

Central retinal artery occlusion in a child with Parry-Romberg syndrome.

Ehmann D, Riyaz R, Greve M.

Can J Ophthalmol. 2014 Feb;49(1):e9-10. doi: 10.1016/j.jcjo.2013.09.012. Epub 2013 Dec 2. No abstract available.

PMID:
24513383
34.

Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.

Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL.

J Biol Chem. 2013 Sep 27;288(39):27960-71. doi: 10.1074/jbc.M113.485979. Epub 2013 Aug 2.

35.

Vogt-Koyanagi-Harada disease in First Nations and Métis of Northern Alberta.

Ehmann D, Tennant MT, Somani R, Rudnisky CJ.

Can J Ophthalmol. 2013 Jun;48(3):146-52. doi: 10.1016/j.jcjo.2012.10.008.

PMID:
23769774
36.

Selective impairment of masculine gender processing: evidence from a German aphasic.

Seyboth M, Blanken G, Ehmann D, Schwarz F, Bormann T.

Cogn Neuropsychol. 2011 Dec;28(8):564-88. doi: 10.1080/02643294.2012.687714.

PMID:
22813070
37.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.

Reck F, Alm RA, Brassil P, Newman JV, Ciaccio P, McNulty J, Barthlow H, Goteti K, Breen J, Comita-Prevoir J, Cronin M, Ehmann DE, Geng B, Godfrey AA, Fisher SL.

J Med Chem. 2012 Aug 9;55(15):6916-33. doi: 10.1021/jm300690s. Epub 2012 Jul 20.

PMID:
22779424
38.

Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Ehmann DE, Jahić H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL.

Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11663-8. doi: 10.1073/pnas.1205073109. Epub 2012 Jul 2.

39.

The kinetic mechanism of S. pneumoniae DNA ligase and inhibition by adenosine-based antibacterial compounds.

Jahić H, Liu CF, Thresher J, Livchak S, Wang H, Ehmann DE.

Biochem Pharmacol. 2012 Sep 1;84(5):654-60. doi: 10.1016/j.bcp.2012.06.017. Epub 2012 Jun 26.

PMID:
22743594
40.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.

Reck F, Alm R, Brassil P, Newman J, Dejonge B, Eyermann CJ, Breault G, Breen J, Comita-Prevoir J, Cronin M, Davis H, Ehmann D, Galullo V, Geng B, Grebe T, Morningstar M, Walker P, Hayter B, Fisher S.

J Med Chem. 2011 Nov 24;54(22):7834-47. doi: 10.1021/jm2008826. Epub 2011 Oct 27.

PMID:
21999508
41.

A homogeneous, high-throughput fluorescence anisotropy-based DNA supercoiling assay.

Shapiro A, Jahic H, Prasad S, Ehmann D, Thresher J, Gao N, Hajec L.

J Biomol Screen. 2010 Oct;15(9):1088-98. doi: 10.1177/1087057110378624.

PMID:
20930214
42.

Question: Can you identify this condition? Filamentary keratitis.

Ehmann D, Schweitzer KD, Baxter S.

Can Fam Physician. 2010 Jul;56(7):667. No abstract available.

43.

Ophthaproblem. Can you identify this condition? Pyogenic granuloma.

Ehmann DS, Schweitzer K, Sharma S.

Can Fam Physician. 2010 Jun;56(6):553, 556. No abstract available.

44.
46.

Nerve fibre layer changes in highly myopic eyes by optical coherence tomography.

Schweitzer KD, Ehmann D, García R.

Can J Ophthalmol. 2009 Jun;44(3):e13-6. doi: 10.3129/i09-058.

PMID:
19506588
47.

Oculoleptomeningeal amyloidosis in 3 individuals with the transthyretin variant Tyr69His.

Schweitzer K, Ehmann D, Garcia R, Alport E.

Can J Ophthalmol. 2009 Jun;44(3):317-9. doi: 10.3129/i09-023.

PMID:
19491989
48.

Biochemical characterization of an inhibitor of Escherichia coli UDP-N-acetylmuramyl-l-alanine ligase.

Ehmann DE, Demeritt JE, Hull KG, Fisher SL.

Biochim Biophys Acta. 2004 May 6;1698(2):167-74.

PMID:
15134649
49.

Chain termination steps in nonribosomal peptide synthetase assembly lines: directed acyl-S-enzyme breakdown in antibiotic and siderophore biosynthesis.

Keating TA, Ehmann DE, Kohli RM, Marshall CG, Trauger JW, Walsh CT.

Chembiochem. 2001 Feb 2;2(2):99-107. No abstract available.

PMID:
11828432
50.

Aminoacyl-SNACs as small-molecule substrates for the condensation domains of nonribosomal peptide synthetases.

Ehmann DE, Trauger JW, Stachelhaus T, Walsh CT.

Chem Biol. 2000 Oct;7(10):765-72.

Supplemental Content

Loading ...
Support Center